ATOS Atossa Genetics Inc.

1.23
+0.04  (+3%)
Previous Close 1.19
Open 1.22
Price To Book 0.66
Market Cap 6945259
Shares 5,646,552
Volume 90,607
Short Ratio
Av. Daily Volume 532,166

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181179636
  2. 8-K - Current report 181178042
  3. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 181177967
  4. 8-K - Current report 181067994
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181012489

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 1H 2018
Endoxifen
Breast cancer - patients who are not responding to Tamoxifen
Phase 2 completion of enrollment announced October 12, 2018.
Endoxifen
Mammographic breast density (MBD)
Phase 2 trial ongoing - noted December 28, 2017.
Fulvestrant
Cuctal carcinoma in situ(DCIS) - invasive breast cancer
Phase 1 preliminary data September 13, 2018 noted drug met safety and tolerability objectives.
Endoxifen
Male breast cancer and Gynecomastia
Phase 2 commencement of enrollment announced July 13, 2018.
Endoxifen
Breast cancer - window of opportunity setting

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181179636
  2. 8-K - Current report 181178042
  3. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 181177967
  4. 8-K - Current report 181067994
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181012489
  6. 8-K - Current report 181012467
  7. 8-K - Current report 18934675
  8. EFFECT - Notice of Effectiveness 18900648
  9. UPLOAD [Cover] - SEC-generated letter
  10. CORRESP [Cover] - Correspondence